RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4413664)

Published in Oncotarget on February 20, 2015

Authors

Jian Zhang1,2,3, Tian-Yi Jiang1,2, Bei-Ge Jiang4, Chun Yang1,2, Ye-Xiong Tan1,2, Ning Yang4, Yu-Fei Pan1,2, Zhi-Wen Ding1,2, Guang-Zhen Yang1, Meng-Chao Wu4, Li-Wei Dong1,2, Hong-Yang Wang1,2,5

Author Affiliations

1: International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University, Shanghai, P. R. China.
2: National Center for Liver Cancer, Shanghai, P.R. China.
3: Current address: Department of Cardiac Surgery, General Hospital of Shenyang Military Area Command, Shenyang, P. R. China.
4: Department of Surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, P.R. China.
5: State Key Laboratory of Oncogenes and related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, P.R. China.

Articles cited by this

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63

Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J (1995) 2.41

Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. Science (2003) 2.15

Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg (2003) 1.97

S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling. Mol Cell (2007) 1.66

Hepatocellular carcinoma: present status and future prospects. J Hepatol (2003) 1.66

Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg (1998) 1.54

Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52

Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer (2001) 1.49

RMP, a novel RNA polymerase II subunit 5-interacting protein, counteracts transactivation by hepatitis B virus X protein. Mol Cell Biol (1998) 1.39

Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol (2011) 1.30

URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell (2011) 1.25

Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol (2000) 1.24

Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology (2010) 1.21

Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy (2011) 1.20

Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol (1997) 1.19

Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg (2009) 1.16

RPB5-mediating protein is required for the proliferation of hepatocellular carcinoma cells. J Biol Chem (2011) 1.03

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol (2004) 1.01

Hepatocellular carcinoma: current management. Curr Probl Surg (2010) 0.98

Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis. BMC Cancer (2011) 0.95

Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection. J Surg Oncol (2000) 0.87

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. Hepatogastroenterology (2012) 0.85

RMP plays distinct roles in the proliferation of hepatocellular carcinoma cells and normal hepatic cells. Int J Biol Sci (2013) 0.83

RMP promotes venous metastases of hepatocellular carcinoma through promoting IL-6 transcription. Oncogene (2014) 0.83

The effect of postoperative TACE on prognosis of HCC: an update. Hepatogastroenterology (2013) 0.80

Early recurrence after curative resection in oligonodular hepatocellular carcinoma. Hepatogastroenterology (2013) 0.79

Postoperative transcatheter arterial chemoembolization should be recommended in the hepatocellular carcinoma treatment guidelines of the American Association for the Study of Liver Diseases. Hepatology (2011) 0.77